{"id":"tezepelumab-ai","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Injection site reaction"}]},"_chembl":{"chemblId":"CHEMBL3707229","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"IL-33 is a cytokine that plays a key role in the development of asthma by promoting the activation and differentiation of immune cells. By blocking IL-33, tezepelumab reduces inflammation and airway hyperresponsiveness in patients with asthma.","oneSentence":"Tezepelumab is an interleukin-33 (IL-33) antagonist that blocks the activity of IL-33, a cytokine involved in the development of asthma.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:38:10.669Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Severe asthma"}]},"trialDetails":[{"nctId":"NCT03968978","phase":"PHASE3","title":"Tezepelumab Home Use Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-05-21","conditions":"Asthma","enrollment":216},{"nctId":"NCT03989544","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics of Tezepelumab After Being Delivered by an Accessorized Pre Filled Syringe or Autoinjector Compared With Vial and Syringe in Healthy Adult Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-06-19","conditions":"Asthma","enrollment":315}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Tezepelumab (AI)","genericName":"Tezepelumab (AI)","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Biologic","firstApprovalDate":"","aiSummary":"Tezepelumab is an interleukin-33 (IL-33) antagonist that blocks the activity of IL-33, a cytokine involved in the development of asthma. Used for Severe asthma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}